Polyethylene glycol effects on the performance of rifampicin-polylactic acid-glycolic acid polymer microspheres

doi:10.3969/j.issn.2095-4344.2015.03.017

Abstract

Abstract:

BACKGROUND: Polylactic acid as a carrier has good biocompatibility, but the burst release of microspheres seriously affects their clinical application.

OBJECTIVE: To investigate the effects of polyethylene glycol on rifampicin-polylactic acid-glycolic acid microspheres in terms of morphologies, drug loading, encapsulation efficiency, in vitro release and burst release.

METHODS: Polylactic acid-glycolic acid polymer was used as a carrier, and polyethylene glycol-rifampicin-polylactic acid-glycolic acid polymer microspheres (experimental group) and rifampicin-polylactic acid-glycolic acid polymer microspheres were prepared using W/O/W emulsifying-solvent evaporation technique. The characteristics of two kinds of microscopes were observed by scanning electron microscopy, drug concentration and cumulative release of rifampicin in the simulated body fluid were detected using high performance liquid chromatography during different periods, and drug loading as well as encapsulation efficiency was also determined in the two groups.

RESULTS AND CONCLUSION: Compared with the control group, in the experimental group, the microspheres were found smooth surface, even distribution, decreased particle size and good dispersion, and the drug loading and encapsulation efficiency were evidently higher. In the experimental group, the largest amount of drug release of the microspheres was within 3 hours, the drug release tended to be stable at 1 day, and the cumulative drug release was less than 20% in1 day. In the control group, the largest amount of drug release was within 3 hours, but the amount was about 1.5 times than that of the experimental group, the drug release also tended to stable at 1 day. The study has shown that polyethylene glycol can improve the pelletizing ratio and reduce the particle size of rifampicin-polylactic acid-glycolic acid microspheres, increase the drug loading and encapsulation efficiency of rifampicin, and reduce the burst release in the process of rifampicin release.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

全文链接：

Key words: Biocompatible Materials, Delayed-Action Preparations, Polyglactin 910

CLC Number:

R318

Yang Zong-qiang, He Ying, Shi Jian-dang. Polyethylene glycol effects on the performance of rifampicin-polylactic acid-glycolic acid polymer microspheres[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(3): 421-426.

Figures/Tables 3

References

[1]施建党,王自立.脊柱结核术后未愈及术后复发的原因探讨[J].中国矫形外科杂志,2005,13(15):1184-1186.
[2]Oga M,Arizono T,Takasita M,et al.Evaluation of the risk of instrumentation as a foreign body in spinal tuberculosis. Clinical and biologic study.Spine (Phila Pa 1976).1993; 18(13):1890-1894.
[3]Alcantar NA,Aydil ES,Israelachvili JN.Polyethylene glycol- coated biocompatible surfaces.J Biomed Mater Res.2000; 51(3):343-351.
[4]Wang Z,Ge Z,Jin W,et al.Treatment of spinal tuberculosis with ultrashort-course chemotherapy in conjunction with partial excision of pathologic vertebrae.Spine J.2007;7(6):671-681.
[5]戈朝晖,王自立,魏敏吉.脊柱结核病灶中抗痨药物浓度的测定[J].中华骨科杂志,2005,25(2):36-40.
[6]德向研,施建党,王自立,等.载三联抗结核药硫酸钙/氨基酸聚合物人工骨体内缓释实验研究[J].中国脊柱脊髓杂志,2013,23(6):成531-536.
[7]Hirota K,Hasegawa T,Nakajima T,et al.Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis.J Control Release. 2010;142(3):339-346.
[8]劳丽春.药物缓释载体材料类型及其临床应用[J].中国组织工程研究与临床康复,2010,14(47):8865-8868.
[9]金丽霞.药物缓释载体材料在医药领域中的研究及应用[J].中国组织工程研究与临床康复,2011,15(25):4699-4702.
[10]刘艳,张志鹏,索绪斌,等.缓控释制剂体外释放度的研究进展[J].时珍国医国药,2011,22(3):701-703.
[11]Fournier E,Passirani C,Montero-Menei CN,et al. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials. 2003; 24(19):3311-3331.
[12]丁小力,王自立,戈朝晖,等.载异烟肼利福平聚乳酸纳米粒的制备及体外释药[J].中国组织工程研究,2012,16(16):2909-2912.
[13]叶美娣,郑彩虹.乳酸-羟基乙酸共聚物(PLGA)微球控释系统的突释[J].中国现代应用药学,2005,22(5):20-23.
[14]Veronese FM,Pasut G.PEGylation: Posttranslational bioengineering of protein biotherapeutics.Drug Discov Today Technol.2008;5(2-3):e57-e64.
[15]Hong SJ,Yu HS,Kim HW.Tissue engineering polymeric microcarriers with macroporous morphology and bone-bioactive surface.Macromol Biosci.2009;9(7):639-645.
[16]黄玲玲,姜志华.PLA的合成及改性研究进展[J].合成树脂及塑料, 2010,27(6):65-69.
[17]张洁琼,曹健,李艳芳,等.聚乳酸的合成•生物降解及应用研究现状[J].安徽农业科学,2010,50(31):17384-17386.
[18]曲文强,夏文龙,孙斌,等.生物降解材料聚羟基乙酸及其共聚物研究进展[J].山东化工,2014,43(3):34-36.
[19]Hirota K,Kawamoto T,Nakajima T,et al.Distribution and deposition of respirable PLGA microspheres in lung alveoli. Colloids Surf B Biointerfaces.2013;105:92-97.
[20]赵先英,张涛,刘毅敏,等.乳酸-羟基乙酸共聚物多肽蛋白类药物微球控释系统的突释与控制[J].西南国防医药,2011,21(8): 920-922.
[21]Hao J,Hu ZM,ZhengQX,et al. Biomineralization of the Surface of PLGA-(ASP-PEG) Modified with the K_(16) and RGD-containing Peptide.Journal of Wuhan University of Technology(Mater Sci Ed).2009;24(5):768-771.
[22]汪求精,孙新林,祝爱萍,等. PLGA/PEG缓释微球的制备与载药性能的研究[J].中华神经医学杂志,2009,8(7):674-677.
[23]王希,张文强,邱蔚芬,等.乳酸-羟基乙酸共聚物缓释微球的制备、性能及应用[J].中国组织工程研究与临床康复,2009,13(12): 2353-2356.
[24]Ito F,Fujimori H,Honnami H,et al.Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique. Colloids Surf B Biointerfaces. 2008;66(1):65-70.
[25]Wu G,Chen L,Li H,et al.Comparing microspheres with different internal phase of polyelectrolyte as local drug delivery system for bone tuberculosis therapy. Biomed Res Int.2014;2014:297808.
[26]黄术.RFP-PLGA骨缓释复合体的初步实验研究[D].中南大学, 2013.
[27]谢鑫鑫,王俊腾,秦利芳,等.聚乙二醇化聚乳酸羟基乙酸纳米粒的制备及体外抗黏性能评价[J].中国医院药学杂志,2012,32(21): 1727-1731.
[28]Jeffery H,Davis SS,O'Hagan DT.The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in- water emulsion solvent evaporation technique.Pharm Res. 1993; 10(3):362-368.
[29]张海龙,高玲美,邵洪伟.聚乳酸载药微球的制备及应用研究进展[J].西北药学杂志,2010,25(2):158-160.
[30]林丽丽.聚乳酸载药系统的研究进展[J].广东化工,2012,39(6): 90-91.
[31]Hasan AS,Socha M,Lamprecht A,et al.Effect of the microencapsulation of nanoparticles on the reduction of burst release.Int J Pharm.2007;344(1-2):53-61.
[32]Liu P,Zhu Q,Jiang J.Distribution of three antituberculous drugs and their metabolites in different parts of pathological vertebrae with spinal tuberculosis. Spine (Phila Pa 1976). 2011;36(20):E1290-E1295.